Hikma Pharmaceuticals Plc Director/PDMR Shareholding (4832S)

TIDMHIK

RNS Number : 4832S

Hikma Pharmaceuticals Plc

17 March 2016

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 17 March 2016: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the Remuneration Committee has made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the EIP were made on 17 March 2016 at a price of 1,815 pence per Ordinary Share (being the closing price the day before grant) as follows:

 
      PDMR         Element B   Element C 
                     Shares      Shares 
  Said Darwazah     68,346      45,100 
 Mazen Darwazah     38,501      25,406 
  Bassam Kanaan     26,090      26,090 
  Majda Labadi      14,530      14,530 
  Riad Mishlawi     19,890      19,890 
 Khalid Nabulsi     20,400      20,400 
    Mike Raya       29,484      29,484 
  Susan Ringdal     15,730      15,730

The Element B share awards will be released to the participants in two years from the date of grant subject to their continued employment and the non-occurrence of forfeiture events during the vesting period as judged by the Remuneration Committee at each anniversary of the grant.

The Element C share awards will be released to the participants in three years from the date of grant subject to their continued employment.

These participants are must retain 50% of the vested shares under elements B and C until five years from the date of grant.

Further details on the EIP, forfeiture criteria and holding period can be found in Hikma's report and accounts for the year ended 31 December 2014 on pages 98, 103 and 104.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

   Peter Speirs                                                                       +44 20 7399 2760

Company Secretary

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBUGDXXDBBGLR

(END) Dow Jones Newswires

March 17, 2016 11:25 ET (15:25 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024